Drug profile · INN
imetelstat
RYTELO
imetelstat (RYTELO) is a telomerase reverse transcriptase inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01XX80
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — imetelstat
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
imetelstat (RYTELO) is a telomerase reverse transcriptase inhibitor.
Key facts
INN imetelstat
Brand RYTELO
Mechanism Telomerase reverse transcriptase inhibitor
Target Telomerase reverse transcriptase
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XX80
Mechanism of action
Telomerase reverse transcriptase inhibitor
Primary target: Telomerase reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is imetelstat?
imetelstat (RYTELO) is a telomerase reverse transcriptase inhibitor.
What is the brand name for imetelstat?
RYTELO is a marketed brand name for imetelstat. Check FDA Drugs@FDA for the current US label holder and prescribing information.